More recently, several large series assessing the genomic landscape of lung adenocarcinoma reported MET exon 14 skipping mutations to occur in approximately 3% of all tumors [1, 2, 10, 11] and 2% of other lung neoplasms [1]. Here, MET is linked to lung adenocarcinoma.